<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND AND PURPOSE: Vascular endothelial growth factor (VEGF) is a major mediator of <z:mpath ids='MPATH_177'>angiogenesis</z:mpath> and a strong vascular permeability factor </plain></SENT>
<SENT sid="1" pm="."><plain>VEGF is known to open the blood-brain barrier (<z:chebi fb="2" ids="33602">BBB</z:chebi>) and induce <z:hpo ids='HP_0002181'>cerebral edema</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>Experimental studies of VEGF antagonism have shown it reduces <z:hpo ids='HP_0002181'>cerebral edema</z:hpo> after <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e>, indicating its potential for prevention of secondary brain damage </plain></SENT>
<SENT sid="3" pm="."><plain>We examined the therapeutic effect of VGA1155 (5- [N-<z:chebi fb="36" ids="29309">Methyl</z:chebi>-N- (4-octadecyloxyphenyl) <z:chebi fb="9" ids="46887">acetyl</z:chebi>] amino-2-<z:chebi fb="36" ids="29309">methyl</z:chebi>-thiobenzoic acid), a novel small molecule <z:chebi fb="68" ids="48706">antagonist</z:chebi> of VEGF, on rat permanent focal <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo> </plain></SENT>
<SENT sid="4" pm="."><plain>METHODS: Permanent middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> (MCAO) was induced with the suture occlusion method </plain></SENT>
<SENT sid="5" pm="."><plain>A single dose of VGA1155 (10mg/kg, i.p.) was administered 30 minutes before the induction of MCAO after which brain water content, Evans blue extravasation, neurological score, <z:mpath ids='MPATH_124'>infarct</z:mpath> volumes and VEGF expression determined by means of ELISA were compared with corresponding values for vehicle injected control rats </plain></SENT>
<SENT sid="6" pm="."><plain>RESULTS: Brain water content and Evans Blue extravasation 24 hours after <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> were not significantly reduced, but, compared with control group, VGA1155 significantly reduced <z:mpath ids='MPATH_124'>infarct</z:mpath> volume (32.0% for VGA1155 vs. 46.7% for control; % volume of hemisphere volume) and improved neurological function 7 days after <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e>, when tissue content of the VEGF group markedly increased to nine times that of the vehicle-treated animals </plain></SENT>
<SENT sid="7" pm="."><plain>CONCLUSION: VGA1155 was found to protect against secondary ischemic brain damage after permanent focal <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo>, although it did not reduce vasogenic <z:hpo ids='HP_0000969'>edema</z:hpo> at 24 hours </plain></SENT>
<SENT sid="8" pm="."><plain>Changes in endogenous VEGF may be related to the therapeutic effect of VGA1155 </plain></SENT>
</text></document>